NCT05942001View on ClinicalTrials.gov

Study of HRS-5041 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

PHASE1RecruitingINTERVENTIONAL

Enrollment

100

Participants

Timeline

Start Date

August 3, 2023

Primary Completion Date

August 31, 2025

Study Completion Date

August 31, 2025

Conditions

Advanced Prostate Cancer

Interventions

DRUG

HRS-5041

HRS-5041 was given oral administration, qd, at a 28-day cycle. Patients may continue to use HRS-5041 until disease progression or unacceptable toxicity occurs.

Trial Locations (1)

Unknown

RECRUITING

Shanghai Jiaotong University School of Medicine, Renji Hospital, Shanghai

All Listed Sponsors

lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY